Cargando…

Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers

BACKGROUND: Rare disease patients and caregivers face uncommon, serious, debilitating conditions often characterised by poor prognosis and limited treatment options. This study aimed to explore what they consider of value when choosing between hypothetical therapeutic options and to quantify both th...

Descripción completa

Detalles Bibliográficos
Autores principales: Morel, T., Aymé, S., Cassiman, D., Simoens, S., Morgan, M., Vandebroek, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881055/
https://www.ncbi.nlm.nih.gov/pubmed/27225337
http://dx.doi.org/10.1186/s13023-016-0444-9
_version_ 1782433899589140480
author Morel, T.
Aymé, S.
Cassiman, D.
Simoens, S.
Morgan, M.
Vandebroek, M.
author_facet Morel, T.
Aymé, S.
Cassiman, D.
Simoens, S.
Morgan, M.
Vandebroek, M.
author_sort Morel, T.
collection PubMed
description BACKGROUND: Rare disease patients and caregivers face uncommon, serious, debilitating conditions often characterised by poor prognosis and limited treatment options. This study aimed to explore what they consider of value when choosing between hypothetical therapeutic options and to quantify both their benefit-risk preferences and the influence of disease context. METHODS: A mixed-methods survey with patients and caregivers was conducted in the United Kingdom across a range of rare diseases. Discrete-choice experiments that compared hypothetical treatment profiles of benefits and risks were used to measure respondent preferences across a set of seven attributes related to health outcomes, safety, and process of care. Bespoke questions on current disease management and the joint use of the 12-item WHODAS 2.0 questionnaire and of two Likert scales capturing self- and proxy-assessed disease-induced threat to life and impairment were implemented to describe disease context. Additionally, qualitative insights on the definitions of value and risk were collected from respondents. RESULTS: Final study sample included 721 patients and 152 informal caregivers, across 52 rare diseases. When choosing between hypothetical novel treatments for rare diseases, respondents attributed most importance to drug response, risk of serious side effects, and the ability to conduct usual activities while on treatment. In contrast, attributes related to treatment modalities were the least important. Respondents expressed a willingness to accept risks in hopes of finding some benefit, such as a higher chance of drug response or greater health improvement potential. Increasing disease severity, impairment or disability, and the lack of effective therapeutic options were shown to raise significantly the willingness to gain benefit through increased risk. CONCLUSIONS: This is the first study performing a quantitative discrete choice experiment amongst patients and caregivers across 52 rare conditions. It enables a more detailed understanding of the relationship between disease context, treatment attributes and the degree of risk respondents are willing to take to gain a specific degree of benefit. Researchers of novel therapeutics for rare diseases should be encouraged to invest in preference elicitation studies to generate rigorous patient evidence and specific regulatory guidance should be issued to acknowledge their importance and their use in marketing authorisations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13023-016-0444-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4881055
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48810552016-05-27 Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers Morel, T. Aymé, S. Cassiman, D. Simoens, S. Morgan, M. Vandebroek, M. Orphanet J Rare Dis Research BACKGROUND: Rare disease patients and caregivers face uncommon, serious, debilitating conditions often characterised by poor prognosis and limited treatment options. This study aimed to explore what they consider of value when choosing between hypothetical therapeutic options and to quantify both their benefit-risk preferences and the influence of disease context. METHODS: A mixed-methods survey with patients and caregivers was conducted in the United Kingdom across a range of rare diseases. Discrete-choice experiments that compared hypothetical treatment profiles of benefits and risks were used to measure respondent preferences across a set of seven attributes related to health outcomes, safety, and process of care. Bespoke questions on current disease management and the joint use of the 12-item WHODAS 2.0 questionnaire and of two Likert scales capturing self- and proxy-assessed disease-induced threat to life and impairment were implemented to describe disease context. Additionally, qualitative insights on the definitions of value and risk were collected from respondents. RESULTS: Final study sample included 721 patients and 152 informal caregivers, across 52 rare diseases. When choosing between hypothetical novel treatments for rare diseases, respondents attributed most importance to drug response, risk of serious side effects, and the ability to conduct usual activities while on treatment. In contrast, attributes related to treatment modalities were the least important. Respondents expressed a willingness to accept risks in hopes of finding some benefit, such as a higher chance of drug response or greater health improvement potential. Increasing disease severity, impairment or disability, and the lack of effective therapeutic options were shown to raise significantly the willingness to gain benefit through increased risk. CONCLUSIONS: This is the first study performing a quantitative discrete choice experiment amongst patients and caregivers across 52 rare conditions. It enables a more detailed understanding of the relationship between disease context, treatment attributes and the degree of risk respondents are willing to take to gain a specific degree of benefit. Researchers of novel therapeutics for rare diseases should be encouraged to invest in preference elicitation studies to generate rigorous patient evidence and specific regulatory guidance should be issued to acknowledge their importance and their use in marketing authorisations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13023-016-0444-9) contains supplementary material, which is available to authorized users. BioMed Central 2016-05-26 /pmc/articles/PMC4881055/ /pubmed/27225337 http://dx.doi.org/10.1186/s13023-016-0444-9 Text en © Morel et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Morel, T.
Aymé, S.
Cassiman, D.
Simoens, S.
Morgan, M.
Vandebroek, M.
Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
title Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
title_full Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
title_fullStr Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
title_full_unstemmed Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
title_short Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
title_sort quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881055/
https://www.ncbi.nlm.nih.gov/pubmed/27225337
http://dx.doi.org/10.1186/s13023-016-0444-9
work_keys_str_mv AT morelt quantifyingbenefitriskpreferencesfornewmedicinesinrarediseasepatientsandcaregivers
AT aymes quantifyingbenefitriskpreferencesfornewmedicinesinrarediseasepatientsandcaregivers
AT cassimand quantifyingbenefitriskpreferencesfornewmedicinesinrarediseasepatientsandcaregivers
AT simoenss quantifyingbenefitriskpreferencesfornewmedicinesinrarediseasepatientsandcaregivers
AT morganm quantifyingbenefitriskpreferencesfornewmedicinesinrarediseasepatientsandcaregivers
AT vandebroekm quantifyingbenefitriskpreferencesfornewmedicinesinrarediseasepatientsandcaregivers